Pfizer (NYSE:PFE) Shares Down 1.2% – Here’s What Happened

Pfizer Inc. (NYSE:PFE)’s share price traded down 1.2% during trading on Monday . The company traded as low as $24.72 and last traded at $24.7470. 36,778,430 shares changed hands during trading, a decline of 14% from the average session volume of 42,647,055 shares. The stock had previously closed at $25.05.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. Wolfe Research reiterated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research note on Tuesday, June 9th. Guggenheim reduced their target price on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Finally, UBS Group restated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.50.

Pfizer Stock Performance

The stock has a 50-day moving average price of $25.17 and a 200 day moving average price of $26.18. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $142.00 billion, a price-to-earnings ratio of 19.01 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the firm earned $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is 131.30%.

Institutional Trading of Pfizer

Institutional investors have recently bought and sold shares of the business. Norges Bank acquired a new position in Pfizer in the fourth quarter valued at approximately $1,830,986,000. Morgan Stanley raised its holdings in Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after buying an additional 13,581,757 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Pfizer by 577.5% in the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after buying an additional 7,489,189 shares in the last quarter. Finally, Capital World Investors boosted its holdings in shares of Pfizer by 51.5% in the 4th quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock valued at $533,704,000 after buying an additional 7,287,194 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.